|
Patent landscape, scope, and claims: |
United States Patent 12,220,392 Scope and Claims: Method-of-Use Coverage for Intravenous Ibuprofen Plus Paracetamol in Post-Operative Surgical Pain
US 12,220,392 is a method-of-treatment patent focused on post-surgical pain managed with an intravenous (IV) aqueous drug solution combining ibuprofen and paracetamol (acetaminophen) in two fixed-dose strength pairings. The independent claim is tied to (i) adult human patients, (ii) IV administration, and (iii) specific dose combinations: 150 mg ibuprofen with 500 mg paracetamol, or 300 mg ibuprofen with 1000 mg paracetamol. Dependent claims narrow to dosing frequency (every 6 hours), exact strength selection, IV infusion duration (15 minutes), and administered volume (100 mL).
Key commercial and legal implication: the claim set targets a specific IV regimen (strength, schedule, and administration conditions). If a competitor uses a different dose ratio, uses oral dosing, uses a different route, or uses a different infusion duration/volume outside the dependent limits, infringement may narrow or shift to doctrine-of-equivalents arguments.
What does US 12,220,392 claim for treating surgical pain with IV ibuprofen and paracetamol?
Short answer: It claims a method of treating surgical pain by IV administering an aqueous solution containing either (a) 150 mg ibuprofen + 500 mg paracetamol or (b) 300 mg ibuprofen + 1000 mg paracetamol to an adult human.
Claim 1: The core scope (independent claim)
Claim 1 elements (as provided):
- Method of treating surgical pain
- Route: intravenously administer
- Patient: adult human
- Dosage form: aqueous solution
- Active dose pairings (fixed combinations):
- Option A: 150 mg ibuprofen + 500 mg paracetamol
- Option B: 300 mg ibuprofen + 1000 mg paracetamol
Implication for claim breadth
- “Method of treating surgical pain” is a use limitation. A competitor must provide evidence of the claimed indication (post-surgical pain) as part of the method steps. If a product is used for another indication (trauma pain, dental pain, generalized pain, migraine), the method claim may not be directly infringed.
- “Aqueous solution” is a formulation/solution limitation. A competitor using a different physical form (e.g., non-aqueous, emulsion, suspension) or a non-solution presentation designed for IV delivery may avoid the exact wording, depending on how “aqueous solution” is interpreted.
- The combination dosing is ratio-locked. Even small changes to ibuprofen/paracetamol amounts can move the regimen out of literal coverage (absent equivalence or an alternative claim not provided).
Claims 3–6: Strength-specific dependent coverage
- Claim 3: aqueous solution contains 150 mg ibuprofen + 500 mg paracetamol
- Claim 4: aqueous solution contains 300 mg ibuprofen + 1000 mg paracetamol
- Claim 5: claim 2 + the 150/500 option
- Claim 6: claim 2 + the 300/1000 option
Implication
- These reinforce “option selection.” If a defendant uses only one of the two strength pairings, there is still literal coverage through the corresponding dependent claim(s), assuming the other dependent elements are met (e.g., 6-hour schedule in claims 5/6).
How do the dependent claims narrow the IV regimen (6 hourly, infusion duration, 100 mL)?
Claim 2: What is the dosing schedule limit?
Claim 2: The aqueous solution is administered on a 6 hourly basis.
Practical effect
- If a competitor administers on a different interval (e.g., q8h, q4h, prn), literal infringement of claim 2 is unlikely.
- However, infringement of claim 1 may still be argued if the regimen still includes the claimed elements of claim 1 and the competitor administers IV ibuprofen/paracetamol in one of the listed combinations for surgical pain, even if outside a 6-hour schedule.
Claim 7: Does infusion time matter?
Claim 7: The IV administration takes place over 15 minutes.
Practical effect
- If a competitor infuses slower or faster than 15 minutes, claim 7 may not be met literally.
- If the product label or method includes variable infusion times, the analysis becomes regimen-specific. Claim 7 is narrower than claim 1 and claim 2.
Claim 8: Does the administered volume matter?
Claim 8: 100 mL of aqueous solution is administered.
Practical effect
- If the same total actives are delivered in a different volume (e.g., 50 mL or 200 mL), literal coverage of claim 8 may be avoided.
- Claim 1 does not include the 100 mL limitation; it is only in the dependent set you provided (claim 8). So a defendant could still face exposure on claim 1 even if volume differs.
What is the implied dosage ratio and how does that define infringement risk?
From your claim text, both listed pairings share a consistent ratio:
- 150 mg ibuprofen : 500 mg paracetamol = 1 : 3.333
- 300 mg ibuprofen : 1000 mg paracetamol = 1 : 3.333
Risk concentration
- Competitors using IV ibuprofen/paracetamol combinations with substantially different ratios (for example, 200 mg ibuprofen + 650 mg paracetamol) reduce the chance of literal infringement of claim 1, unless the combination falls within equivalent boundaries.
- Competitors matching the ratio but using different totals (for example, 180 mg ibuprofen + 600 mg paracetamol) also miss literal coverage because the claim is specific to 150/500 and 300/1000.
Commercial design consideration
- A product designed to “cover” these strengths will face high probability of claim 1 risk if used as described.
- A product designed around intermediate doses may shift risk away from literal infringement but still invite doctrine-of-equivalents arguments if claim interpretation later broadens “comprising” logic or if equivalents are argued around dose amounts and formulation parameters.
What types of products fall inside or outside the scope: route, indication, and formulation?
Likely within scope (literal infringement profile)
- IV aqueous solution given to adults for surgical pain
- Total actives match one of the two pairs:
- 150 mg ibuprofen + 500 mg paracetamol
- 300 mg ibuprofen + 1000 mg paracetamol
- If using dependent claims, also:
- administered every 6 hours (claim 2)
- infused over 15 minutes (claim 7)
- delivered as 100 mL (claim 8)
Likely outside scope (literal avoidance levers)
- Non-IV route: oral, intramuscular, subcutaneous, rectal, transdermal.
- Non-aqueous formulation: if designed as non-aqueous or not a solution (depending on definition).
- Different indication: not “surgical pain” or not for post-operative pain.
- Different dose pairings: not matching either 150/500 or 300/1000.
- Different regimen parameters: not q6h, not 15-minute infusion, not 100 mL.
How strong is the patent estate based on method-of-use claim structure?
Key strength factors
- Fixed-dose combination: Two precise dosing options can be directly mapped to product label strengths and administration instructions.
- Regimen limitations in dependents: q6h, 15-minute infusion, and 100 mL can align with clinical protocols, which strengthens enforceability when the accused method mirrors the protocol.
- Adult population limitation: narrows claims against pediatric off-label uses, focusing on adult administration.
Key vulnerability factors (enforcement focus)
- Method-of-use patents require proof of use. Enforcing against commercial supply typically relies on label instructions, clinical protocols, or evidence that customers administer the drug exactly as claimed.
- Indication boundary: “surgical pain” can be contested if use is characterized as a different pain state or as general analgesia without specifying surgical context.
- Literal mapping risk for competitors: because the dose amounts and formulation conditions are tightly stated, a small change may escape literal infringement.
What patent litigation risks arise from US 12,220,392 in generic or biosimilar contexts?
US 12,220,392 is a small-molecule combination IV method concept (ibuprofen + paracetamol), not a biologic. The litigation risk profile typically shows up through:
- challenges to exclusivity/labeling under Hatch-Waxman if a listed product is referenced,
- Paragraph IV disputes if the patent is in an FDA listing and the generic files for approval,
- or direct method-of-use infringement suits if the label or promotional materials encourage the claimed surgical-pain regimen.
Procedural posture that matters
- Enforcement usually requires tying the accused product’s use to the claimed method steps.
- If a generic product’s label does not instruct “surgical pain” use or does not specify the exact regimen parameters, plaintiffs often rely on evidence beyond label (real-world use, prescribing patterns, investigator brochures, or clinical trial protocols).
What generic entry risks exist for IV ibuprofen plus paracetamol methods?
Generic entry risks depend on whether US 12,220,392 covers:
- an already-approved reference drug using the claimed dose strengths and IV regimen, and
- whether the Orange Book lists the patent for that NDA/ANDA.
You provided the claims but not:
- the patent’s publication history,
- the assignee(s),
- the referenced FDA product(s),
- or whether US 12,220,392 is listed in the Orange Book.
Without those facts, a precise launch-risk map across specific generic applicants is not producible from claim text alone.
What formulations are protected: aqueous solution with specific strength pairings?
The claim set does not list excipients, salts, pH targets, or solubilizers. Protection is therefore centered on:
- the aqueous solution state,
- the exact ibuprofen and paracetamol masses per dose option,
- plus dependent regimen elements (q6h, infusion duration, 100 mL).
From a design-around standpoint, a competitor’s biggest “freedom-to-operate” levers are:
- changing the dose amounts so they do not match 150/500 or 300/1000,
- adjusting volume so it is not 100 mL,
- changing infusion time away from 15 minutes,
- and aligning labeling and use away from “surgical pain” as a claimed indication.
How does US 12,220,392 compare with adjacent method-of-use patents for IV analgesic combinations?
Within the IV analgesic space, patents typically cluster in three buckets:
- Formulation patents (composition, excipients, pH, stability, solubilization)
- Method-of-use patents (indication, patient population, route, dose regimen)
- Administration/device/process patents (infusion systems, methods of delivery)
US 12,220,392 is primarily a method-of-use / regimen patent because it locks route (IV), indication (surgical pain), and dose strength pairings, with dependents adding schedule, infusion time, and volume.
This is generally stronger for preventing protocol-consistent use but weaker against competitors who reconfigure dose/infusion parameters or avoid label-advised administration patterns.
Key Takeaways
- US 12,220,392 claims a method of treating surgical pain in adult humans via IV aqueous solutions with exact combination doses: 150 mg ibuprofen + 500 mg paracetamol or 300 mg ibuprofen + 1000 mg paracetamol.
- Dependent claims narrow to a q6h schedule (claim 2), specific strength selections (claims 3–6), 15-minute infusion duration (claim 7), and 100 mL administered volume (claim 8).
- The enforceability profile is method-use dependent: infringement hinges on real-world or label-driven administration that matches the claimed indication and regimen.
- Design-around opportunities concentrate on changing dose totals/ratios, altering infusion parameters (time/volume/schedule), and avoiding “surgical pain” method use.
FAQs
1) What elements of claim 1 are hardest for a competitor to change?
The route (IV), the adult patient population framing, the aqueous solution requirement, and the fixed-dose combinations (150/500 or 300/1000).
2) Does a different infusion time automatically avoid infringement?
It avoids the narrower dependent limitation in claim 7 (15 minutes), but may still leave exposure under claim 1 if the accused method otherwise matches.
3) Can a competitor avoid claim 2 by using a different dosing interval?
Literal infringement of claim 2 requires 6-hour administration; using a different interval is a direct design-around for that dependent claim, while claim 1 may remain relevant.
4) If the same actives are given in a different volume, is the patent avoided?
Claim 8 requires 100 mL. A different volume avoids claim 8 literally, but does not by itself avoid claim 1.
5) Is US 12,220,392 a formulation patent or a method-of-use patent?
Based on the provided claims, it is a method-of-use patent centered on the IV administration regimen and surgical pain indication, not an excipient/pH/process composition claim.
References
- United States Patent 12,220,392. Claims provided in the prompt (verbatim claim language as supplied).
More… ↓
⤷ Start Trial
|
